Právní předpis byl sestaven k datu 17.03.2026.
Zobrazené znění právního předpisu je účinné od 01.01.2025.
419
XXXXXXXX XXXXX
xx xxx 11. xxxxxxxx 2024,
xxxxxx xx mění xxxxxxxx xxxxx č. 463/2013 Xx., o seznamech xxxxxxxxxx xxxxx, ve xxxxx xxxxxxxxxx xxxxxxxx
&xxxx;
Xxxxx xxxxxxxx xxxxx §44c xxxx. 1 a 2 zákona č. 167/1998 Sb., x xxxxxxxxxx xxxxxxx a x xxxxx xxxxxxxxx xxxxxxx zákonů, xx xxxxx xxxxxx x. 273/2013 Xx. a xxxxxx č. 366/2021 Xx.:
Xx. I
Nařízení xxxxx x. 463/2013 Xx., x seznamech xxxxxxxxxx xxxxx, xx xxxxx xxxxxxxx xxxxx x. 243/2015 Xx., xxxxxxxx xxxxx x. 46/2017 Xx., xxxxxxxx xxxxx x. 30/2018 Xx., xxxxxxxx vlády č. 242/2018 Xx., nařízení xxxxx x. 184/2021 Xx., xxxxxxxx xxxxx x. 159/2022 Sb., xxxxxxxx xxxxx x. 228/2023 Xx., xxxxxxxx xxxxx x. 52/2024 Xx. x xxxxxxxx xxxxx x. 176/2024 Xx., se xxxx xxxxx:
1. X xxxxxxx xxxxxxx x. 1 xx xxx xxxxx, xx xxxxxx je xx xxxxxxx x xxxxxx „Xxxxxxxxxxx nechráněný xxxxx (XXX) v xxxxxx xxxxxx“ xxxxxxx xxxxx „Thebakon“, vkládá xxxx xxxxx, ve xxxxxx je xx xxxxxxx x xxxxxx „Xxxxxxxxxxx xxxxxxxxxx xxxxx (XXX) x xxxxxx xxxxxx“ uvedeno slovo „Xxxxxxxxxxxx“, xx xxxxxxx x názvem „Xxxxxxxx xxxxx podle XXXXX“ xx xxxxxxx xxxxx „xxxxxx 4-(N-(2-methoxyacetyl)anilin)-1-(2-thiofen-2-ylethyl)piperidin-4-karboxylát“ x xx xxxxxxx x xxxxxx „Poznámka“ xxxx xxxxxxx xxxxx „A-3080, Xxxxxxx“.
2. Xxxxxxx č. 3 xxx:
„Xxxxxxx č. 3
Xxxxxx č. 3 xxxxxxxx xxxxx
|
Xxxxxxxxxxx nechráněný xxxxx (XXX) v českém xxxxxx / xxxxxx xxxxx |
Xxxxx xxxxxxxxxxx xxxxxxxxxx xxxxx nebo xxxxx xxxxxx xxxxx |
Xxxxxxxx název xxxxx XXXXX |
Xxxxxxxx |
|
Xxxxxxxxxxxxxxxxxxxx |
xxxxxxxxxxxxxxxxxxxx |
X-xxxxx-X-(1-xxxxxx-xxxxxxxxx-4-xx)-xxxxxxxx |
XXX 73750 |
|
Xxxxxxxxxxxxxx |
X-xxxxx-X-[1-(2-xxxxxxxxxx)-4-xxxxxxxxxxx]xxxxxxxx |
||
|
Xxxxxxxxxxxxxxxx |
Xxxxxxxxxxxxx |
X-xxxxx-X-[1-(2-xxxxxxxxxx)xxxxxxxxx-4-xx]xxxx-2-xxxxxx |
|
|
XX-7921 |
3,4-xxxxxxx-X-{[1-(xxxxxxxxxxxxx)xxxxxxxxxx]xxxxxx}xxxxxxxx |
||
|
XX-237 |
xxxxxxxxxx; 1-X-xxxxxxx-4- cinnamylpiperazine; |
1-[4-(3-fenylprop-2-en-1-yl)piperazin-1-yl]butan-1-on |
|
|
AP-238 |
1-[2,6-dimethyl-4-(3-fenylprop-2-enyl)piperazin-1-yl]propan-1-on |
||
|
Benzodioxolfentanyl |
BZD-F; xxxxxxxxxxxx-X |
X-xxxxx-X-[1-(2-xxxxxxxxxx)xxxxxxxxx-4-xx-1-2X-1,3-xxxxxxxxxxx-5-xxxxxxxxxx |
|
|
Xxxxxxxxxxxxxxxxxxxxx |
X-xxxxx-X-(1-xxxxxx-xxxxxxxxx-4-xx)xxxxxxxx |
||
|
Xxxxxxxxxxxxxxx |
xxxxxxxxxxxxx |
X-xxxxx-X-[1-(2-xxxxxxxxxx)xxxxxxxxx-4-xx]xxxxxxxx |
|
|
Xxxxxxxxxxxxxx |
Xxxxxx-X; X4129 |
X-xxxxx-X-[1 -(xxxxxxxxxxx)xxxxxxxxx-4-xx]xxxxxxxxxx |
|
|
Xxxxxxxxxxxxxxxxxxxxx |
Xxxxxx XxX |
X-(1-xxxxxxxxxxxxxxx-4-xx)-X-xxxxxxxxxx-2-xxxxxxxxxx |
|
|
Xxxxxxxxxx |
X 4793x; X 47931E |
4-brom-N-(2-(dimethylamino) xxxxxxxxxx) xxxxxxxx |
|
|
Xxxxxxx |
Xxxxxxxxx |
3-{1-[1-(4-xxxxxxxxx)xxxxx]xxxxxxxxx-4-xx}-1X-xxxxxxxxxxxx-2-xx |
|
|
Xxxxxxxxxxx |
2-[(4-xxxxxxxxxxx)xxxxxx]-X,X-xxxxxxx-5-xxxxx-xX-xxxxxxxxxxxx-1-xxxxxxxxx |
||
|
4-Xxxxxxxxxxxxxxxxxxxxx |
4-Xx-xXX |
X-(4-xxxxxxxxxx)-2-xxxxxx-X-[1-(2-xxxxxxxxxx)-4-xxxxxxxxxxx]xxxxxxxxxx |
|
|
Xxxxxxxxxxxxxxxxxxx |
xxxxxxxxxxx-X; XX-X |
X-xxxxx-X-[1-(2-xxxxxxxxxx)xxxxxxxxx-4-xx]xxxxxxxxxxxxxxxxxxxxx |
|
|
Xxxxxxxxxxxxxxxxxxx |
X-xxxxx-X-[1-(2-xxxxxxxxxx)xxxxxxxxx-4-xx]xxxxxxxxxxxxxxxxxxxxx |
||
|
Xxxxxxxxxxxxxxxx |
X530 |
4-(4-xxxxxxxxxx)-2,2-xxxxxxx-1-(1-xxxxxxxxxxxx)-1-xxxxxxx |
|
|
Xxxxxxxxxx |
4,5α-xxxxx-17-xxxxxxxxxxxxxx-3-xx |
||
|
Xxxxxxxxxxxx-2-xxxxx xxxxxxxx |
X-(2-xxxxxxxxxx)-1-(2-xxxxxxxxxx)xxxxxxxxx-4-xxxx |
||
|
Xxxxxxxxxxxx-4-xxxxx fentanyl |
N-(4-fluorfenyl)-1-(2-fenylethyl)piperidin-4-amin |
||
|
Dipyanon |
4,4-difenyl-6-(pyrrolidin-1-yl)heptan-3-on |
||
|
Etazen |
etodesnitazene |
2-[2-[(4-ethoxyfenyl)methyl]benzimidazol-1-yl]-N,N-diethylethanamin |
|
|
Ethylenoxynitazen |
2-{2-[(2,3-dihydro-1-benzofuran-5-yl)methyl]-5-nitro-1H-benzimidazol-1-yl}-N,N- diethylethan-1-amin |
||
|
Etometazen |
5-methyl xxxxxxxxxxxxx; 5-xxxxxx xxxxxxxxxxxxxxxxxx |
2-[(4-xxxxxxxxxxx)xxxxxx]-X,X-xxxxxxx-5-xxxxxx-1X-xxxxxxxxxxxx-1-xxxxxxxxx |
|
|
Xxxxxxxxxxxxxx |
X-xxxxxxxxxxxxxxxxxxxxx |
2-(4-xxxxxxxxxxxx)-5-xxxxx-1-(2-(xxxxxxxxx-1-xx)xxxxx)-1X-xxxxx[x]xxxxxxxx |
|
|
Xxxxxxxxxxxx |
2-[(4-xxxxxxxxxxx)xxxxxx]-5-xxxxx-1-(2-xxxxxxxxxx-1-xxxxxxx)-1X-xxxxxxxxxxxxx |
||
|
Xxxxxxx |
(5X,6X,7X,14X)-4,5-xxxxx-7-[(2X)-2-xxxxxxxxxxxxx-2-xx]-6-xxxxxxx-17-xxxxxx-6,14-xxxxxxxxxxxxxx-3-xx |
||
|
Xxxxxxxx xxxxxxxxx xxxxxx |
xxxxxxxxxxxxx |
X-xxxxx-X-[1-(2-xxxxxxxxxx)-4-xxxxxxxxxxx]-xxxxxxxxx |
|
|
3 -Xxxxxxxxxxxxxxxxxxxxx |
β'-xxxxxxxxxxxxx |
X-xxxxx-X-[1-(2-xxxxxxxxxx)xxxxxxxxx-4-x]-3-xxxxxxxxxxxxxxx |
xxxxxxxxxxxxxxxxxxxxxx |
|
Xxxxxxxxxx |
X,X-xxxxxxx-2-{2-[(4-xxxxxxxxxx)xxxxxx]-5-xxxxx-1X-xxxxxxxxxxxx-1-xx}xxxxxxxxx |
||
|
2’-Xxxxx-2-xxxxx-3-xxxxxxxxxxxxxx |
X-(1-(2-xxxxxxxxxxxxx)-3-xxxxxxxxxxxxxxx-4-xx)-X-(2-xxxxxxxxxx)xxxxxxxxxxx |
||
|
4-Xxxxx-xxxxxxxxxxxxx |
4X-XX |
X-(4-xxxxxxxxxx)-X-[(1-(2-xxxxxxxxxx)-4-xxxxxxxxxxx)]xxxxxxxxx |
|
|
4-Xxxxx-xxxxxxxxxxxxxxxxxxxxxxxxx |
xxxx-xxxxxxxxxxxxxxxxxxxxxx- fentanyl |
N-(4-fluorfenyl)-N-(1-benzylpiperidin-4-yl)-cyklopropankarboxamid |
|
|
2-Fluorfentanyl |
Ortofluorfentanyl |
N-(2-fluorfenyl)-N-[1-(2-fenylethyl)-4-piperidinyl]propanamid |
2-FF, x-XX |
|
3-Xxxxxxxxxxxxx |
Xxxxxxxxxxxxxxxxx |
X-(3-xxxxxxxxxx)-X-[1-(2-xxxxxxxxxx)-4-xxxxxxxxxxx]xxxxxxxxxx |
3-XX, x-XX |
|
4-Xxxxxxxxxxxxxxxxxxxx |
xxxx-xxxxxxxxxxxxxxxxxxxx; 4X-xxxxxxxxxxxxxxx |
X-(4-xxxxxxxxxx)-X-(1-xxxxxxxxxxxxxxxxx-4-xx)xxxxx-2-xxxxxxxxxx |
|
|
4-Xxxxxxxxxxxxxxxxxxxxx |
4X-1XX |
X-(4-xxxxxxxxxx)-2-xxxxxx-X-[1-(2-xxxxxxxxxx)-4-xxxxxxxxxxx]xxxxxxxxxx |
|
|
3-XxxxxxxxxxxxxxxxxXxxxxxxxx |
xxxxx-xxxxxxxxxxxxxxxxxx- xxxxxxxx |
X-(3-xxxxxxxxxx)-2-xxxxxxx-X-[1-(2-xxxxxxxxxx)xxxxxxxxx-4-xx]xxxxxxxx |
|
|
2X-xxxxxxx |
2-[xx(xxxxx-2-xx)xxxxx]-1-[1-(2-xxxxxxxxxxx)-1X-xxxxxx-2-xx]xxxxx-1-xx |
||
|
Xxxxxxx XX-17 |
X-[2-(xxxxxxxxxxxxx)xxxxxxxxxx]-X-xxxxx-xxxxx-2-xxxxxxxxxx |
||
|
Xxxxxxxxxxxxxxx |
XX-X; 2-xxxxxxxxxxxxxxxx |
X-xxxxx-X-[1-(2-xxxxxxxxxx)xxxxxxxxx-4-xx]-xxxxx-2-xxxxxxxxxx |
|
|
(xxx)Xxxxxxx-X-xxxxxxxx X-xxxxxx xxxxxx |
X-(1-xxxxxxxxxxxxxxx-4-xx)-X-(4-xxxxxxxxxx)xxxxxxxxx |
||
|
Xxxxxx |
(5X,6X)-4,5-xxxxx-17-xxxxxxxxxxxx-7-xx-3,6-xxxx-xxxxxxxx |
||
|
4-xxxxxxxxxxxxxxxxxxxx |
4-XX-XX; x-xxxxxxxxxxxxxx xxxxxxxx |
X-(4-xxxxxxxxxxxx)-X-[1-(2-xxxxxxxxxx)xxxxxxxxx-4-xx]-xxxxxxxxx |
|
|
Xxxxxxxxxxxxxxxx |
2-xxxxxx-X-xxxxx-X-[1-(2-xxxxxxxxxx)xxxxxxxxx-4-xx]xxxxxxxxxx |
||
|
Xxxxxxxxx-X-47700 |
3,4-xxxxxxxX-[2-(xxxxxxxxxxxxx)xxxxxxxxxx]-X-(xxxxxx-2-xx)xxxxxxxx |
||
|
Xxxxxxxxxxxx |
X,X-xxxxxxx-2-[[4-(1-xxxxxxxxxxxx)xxxxx]xxxxxx]-5-xxxxx-1X-xxxxxxxxxxxx-1-xxxxx xxxx |
||
|
Xxxxxxxx-xxxxxxxx |
(4-xxxxxxxxx)-(1-(xxxxxxxxxxxxx)-4-xxxxxxx-4-xxxxxxxxxxxxxxxxxx)xxxxxxxx |
||
|
Xxxxxxxxxxx |
1-[4-(3-xxxxxxx xxxxx)-1 -xxxxxxxxxxxxxxx-4-xx]xxxxxx-1-xx |
||
|
Xxxxxx |
X výjimkou xxxxxx xxx léčebné xxxxxxx xxxxxxx v xxxxxxx x.&xxxx;1 |
||
|
Xxxxxxxxxxxxxxxx |
(2X)-X-xxxxx-X-[1-(2-xxxxxxxxxx)xxxxxxxxx-4-xx]-2-xxxxxxxxx |
||
|
Xxxxxxxxxxxxxxxxxxxxx |
Xxxxxxx-XxX |
2-xxxxxxx-X-xxxxx-X-[1-(2-xxxxxxxxxx)xxxxxxxxx-4-xx]xxxxxxxx |
|
|
4-Xxxxxxxxxxxxxxxxxxxx |
4-XxX-XX |
X-(4-xxxxxxxxxxxx)-X-[1-(2-xxxxxxxxxx)xxxxxxxxx-4-xx]xxxxxxxxx |
|
|
2-Xxxxxxxxxxxxxxxxxxxx |
x-xxxxxxxxxxxxxxxxxxxx |
X-(2-xxxxxxxxxxx)-X-[1-(2-xxxxxxxxxx)-xxxxxxxxx-4-xx]-xxxxxxxx |
|
|
2-Xxxxxx-XX-237 |
2-xxxxxx-xxxxxxxxxx |
1-[2-xxxxxx-4-(3-xxxxxxxxx-2-xx-1-xx)xxxxxxxxx-1-xx]xxxxx-1-xx |
|
|
3,4-Xxxxxxxxxxxxx-X-47700 |
3,4-XXX-X-47700; 3,4-XXX-47700; MDU-47; MDU-47700 |
N-(2-(dimethylamino)cyklohexyl)-N-methylbenzo[d][1,3]dioxol-5-karboxamid |
|
|
α-Methylfentanyl xxxxxxxxx xxxxxx |
XX; B-F |
2-methyl-N-fenyl-N-[1-(1-fenylpropan-2-yl)piperidin-4-yl]propanamid |
|
|
3 -XxxxxXxxxxxxxXxxxxxxxx |
β'-xxxxxXxxxxxxxXxxxxxxxx |
X-xxxxx-X-[1-(2-xxxxxxxxxx)-xxxxxxxxx-4-xx]-3-xxxxxxxxx-2-xxxxxx |
|
|
Xxxxxxxxxxxxxx |
X,X-xxxxxxx-2-[2-[(4-xxxxxxxxxxxx)xxxxxx]xxxxxxxxxxxx-1-xx]xxxxxxxxx |
||
|
Xxxxxxxxxxx |
X,X-xxxxxxx-2-[2-[(4-xxxxxxxxxxxx)xxxxxx]-5-xxxxxxxxxxxxxxxxx-1-xx]xxxxxxxxx |
||
|
Xxxxxxxxxxxxx |
2-(4-xxxxxxxxxxxxx)-5-xxxxx-1-(2-(xxxxxxxxxx-1-xx)xxxxx)-1X-xxxxx[x]xxxxxxxx |
||
|
XX-45 |
1-xxxxxxxxxx-4-(1,2-xxxxxxxxxxxx)xxxxxxxxx |
||
|
X-xxxxxxxxxxxxxxxxxx |
2-[2-[(4-xxxxxxxxxxx)xxxxxx]-5-xxxxx-xxxxxxxxxxxx-1-xx]-X-xxxxx-xxxxxxxxx |
||
|
X-xxxxxxxxxxxxxxxxxxxx |
X-xxxxx-2-[2-[(4-xxxxxxxxxxxxxxx)xxxxxx]-5-xxxxx-xxxxxxxxxxxx-1-xx]xxxxxxxxx |
||
|
X-xxxxxx X-47931X |
X-xxxxxxxxxxxxxxxx |
4-xxxx-X-(2-(xxxxxxxxxxxxx)xxxxxxxxxx)-X-xxxxxxxxxxxxxx |
|
|
Xxxxxxxxxx |
xxxxx 2-xxxxxxxxxxx-1-xxxxxxxxxxxxx-3-xx-1-xxxxxxxxxx |
||
|
X-XXXX; xxxxxxxxxxxxxxxxxxxxxxxx |
3-(4-xxxxxx-1-xxxxxxxxxxxxxxx-4-xx)xxxxx xxxxxx |
||
|
XXxxxxxxxx |
X-3217 |
X-(2-xxxxxxxxxx)-2-xxxxxxx-X-[1-(2-xxxxxxxxxx)xxxxxxxxx-4-xx]xxxxxxxx |
|
|
Xxxxxxxxxxxxxxxxxxx |
xxxxxxxxxxxxxx, XXX, 127X49 |
1-(4,4-xx(xxxxxxx-2-xx)xxx-3-xx-2-xx)xxxxxxxxx |
|
|
Xxxxxxxxxxxx |
X,X-xxxxxxx-5-xxxxx-2-[(4-xxxxxxxxxxxx)xxxxxx]-1-X-xxxxxxxxxxxx-1-xxxxxxxxx |
||
|
Xxxxxxxxxxxxxx |
5-xxxxx-2-[(4-xxxxxxxxxxxxx)xxxxxx]-1-(2-xxxxxxxxxx-1-xxxxxxx)xxxxxxxxxxxxx |
||
|
Xxxxxxxxxx x&xxxx;xxxxxx |
|||
|
Xxxxxxxxxxxxxxxxxxxxxxx |
XXX-X |
X-(1-xxxxxxxxxxxxxxxxxxx-4-xx)-X-xxxxxxxxxxxxxxxxxxxx-2-xxxxxxxxxx |
|
|
Xxxxxxxxxxxxxxxxxxxxxxxxxxxxxx |
XXXX-xxxxxxxx; XXXX-X |
X-xxxxx-X-[1-(2-xxxxxxxxxx)xxxxxxxxx-4-xx]-2,2,3,3-xxxxxxxxxxxxxxxxxxxxxx-1- xxxxxxxxxx |
|
|
Xxxxxxxxxxxxxxx |
2-xxxxxxxxxxx xxxxxxxx |
X-(1-xxxxxxxxxxxxxxxxx-4-xx)-X-xxxxxxxxxxxx-2-xxxxxxxxxx |
|
|
4-(Xxxxxxxxxxxxxx) X-47700 |
X-(2-(xxxxxxxxxxxxx)xxxxxxxxxx)-X-xxxxxx-4-(xxxxxxxxxxxxxx)xxxxxxxx |
||
|
X-47700 |
3,4-xxxxxxx-X-[2-(xxxxxxxxxxxxx)xxxxxxxxxx]-X-xxxxxxxxxxxxxx |
||
|
X-48800 |
2-(2,4-xxxxxxxxxxxx)-X-(2-(xxxxxxxxxxxxx)xxxxxxxxxx)-X-xxxxxxxxxxxxxx |
||
|
X-49900 |
3,4-xxxxxxx-X-[2-(xxxxxxxxxxxx)xxxxxxxxxx]-X-xxxxxxxxxxxxxx |
||
|
X-50488 |
3,4-xxxxxxx-X-xxxxxx-X-[2-(1-xxxxxxxxxxxx)xxxxxxxxxx] benzenacetamid |
||
|
U-51754 |
2-(3,4-dichlorfenyl)-N-[2-(dimethylamino)cyklohexyl]-N-methylacetamid |
||
|
ValeryIfentanyl |
TCE, XX |
X-xxxxx-X-[1-(2-xxxxxxxxxx)-4-xxxxxxxxx]xxxxxxxxxx; xxxxxxxx xxxxxxxxxx analog |
Včetně xxxx omamných xxxxx xxxxxxxxx x xxxx xxxxxxx ve xxxxx xxxxxxxxx, kdy xxxx xxxx xxxxx xxxxxxxxx.“.
3. X xxxxxxx xxxxxxx x. 6 se xxx xxxxx, xx xxxxxx je ve xxxxxxx x xxxxxx „Xxxxxxxxxxx xxxxxxxxxx xxxxx (XXX) x xxxxxx xxxxxx“ uvedeno xxxxx „Xxxxxxxxxxxxx“, xxxxxx xxxx xxxxx, xx xxxxxx xx ve sloupci x xxxxxx „Mezinárodní xxxxxxxxxx název (XXX) x xxxxxx xxxxxx“ xxxxxxx xxxxx „Xxxxxxxxxxxxxxxx“, xx xxxxxxx s xxxxxx „Xxxxx mezinárodní xxxxxxxxxx xxxxx nebo xxxxx xxxxxx název“ xx uveden xxxx „XXX“, xx sloupci x xxxxxx „Xxxxxxxx xxxxx podle XXXXX“ xx xxxxxxx xxxxx „xxxxxx-2-xx“ x ve xxxxxxx x názvem „Xxxxxxxx“ je xxxxxxx xxxxx „xxxxx-xxxxxxxxxxxxx“.
Xx. XX
Xxxxxxxxx xxxxxxx
Xxxx xxxxxxxx xxxx xxxxxxxx x xxxxxxx xx xxxxxxxx Xxxxxxxxxx parlamentu x Rady (XX) 2015/1535 xx xxx 9. xxxx 2015 x xxxxxxx xxx xxxxxxxxxxx xxxxxxxxx x xxxxxxx xxxxxxxxxxx předpisů x předpisů xxx xxxxxx xxxxxxxxxx xxxxxxxxxxx.
Xx. XXX
Xxxxxxxx
Xxxx xxxxxxxx xxxxxx xxxxxxxxx dnem 1. xxxxx 2025, x xxxxxxxx ustanovení čl. I bodu 3, xxxxx xxxxxx účinnosti xxxx 1. dubna 2025.
&xxxx;
Xxxxxxxx xxxxx:
xxxx. XxXx. Xxxxx, Xx.X., LL.M., x. r.
Místopředseda xxxxx x xxxxxxx zdravotnictví:
prof. XXXx. Xxxxx, XXx., XXX, EBIR, v. x.
Xxxxxxxxx
Xxxxxx xxxxxxx x. 419/2024 Xx. xxxxx xxxxxxxxx dnem 1.1.2025, x xxxxxxxx xxxxxxxxxx čl. I xxxx 3, xxxxx xxxxxx xxxxxxxxx 1.4.2025.
Xxxxx xxxxxxxxxxxx právních xxxxx xxxxxx právních xxxxxxxx v odkazech xxxx xxxxxxxxxxxxx, pokud xx jich xxxxxx xxxxxxxxx xxxxx xxxxx xxxxxxxxx xxxxxxxx xxxxxxxx.